Search results
-
Dr Catherine Lindon
... role of substrate proteolysis in the precisely coordinated events giving rise to two daughter cells at the end of mitosis. The Aurora ...
-
Dr Athena Matakidou
... modify the mouse renal apithelium and replicate the genetic events observed in human renal cell carcinoma. The development of reproducible ...
-
Dr Mariann Bienz
... cell compartment. Our aim is to understand the molecular events underlying Wnt signal transduction. We focus on positively-acting ...
-
Dr Dario Bressan
... for the spatial and temporal control of biological events in vivo. Specifically, I am using photochemically caged ligands and ...
-
Dr Frank McCaughan
My research is focused on understanding the early driver events that are critical to the development of squamous lung cancer (SQC) and ...
-
Professor Gillian Murphy
... by trafficking which allows specific localisation in events such as cell invasion. The identification of the importance of specific ...
-
Dr James Nathan
Cellular mechanisms of oxygen and metabolite sensing: ...
-
Dr James Rudd
... arteries as a predictor of plaque rupture and clinical events. Additionally, I use non-invasive imaging methods such as PET, MRI and ...
-
Ms Paola Marco
... The inhibitor can be washed out, allowing us to study events in a more flexible way. I will introduce these mutants in RPE cells to ...
-
Dr Marisa Segal
... morphogenesis in S. cerevisiae we have focused on the events that determine SPB asymmetry or spindle polarity, i.e. the mechanisms ...
-
Dr David Gilligan
David Gilligan is a Consultant Clinical Oncologist at Addenbrooke's and Papworth Hospitals in Cambridge. He is the Clinical Lead for Acute Oncology at Addenbrooke's. He trained in pre clinical medicine at the University of Edinburgh and clinical...
-
Mr David Thurtle
Radiological assessment of prostatic osseous metastases. Robotic-assisted laparoscopic prostatectomy. Early detection of prostate cancer. Risk Prediction in prostate cancer
-
Professor David Glover
Our laboratory studies the regulation of progression through mitosis and meiosis in animal cells. The high degree of evolutionary conservation of these regulatory mechanisms means that findings in model organisms are readily applicable to human cells....
-
Dr Roisin Owens
Our group works on integrating biological models with electronic devices to generate systems that can be predictive of real biological systems, for drug discovery and therapeutics. We combine expertise in a wide range of disciplines including...
-
Mr Thierry Lefebvre
Radiotherapy is often prescribed in oncology clinics to treat solid tumours and to limit the development and the propagation of cancer cells. The lack of oxygenation seen in some tumour regions under chaotic and unrestricted cellular growth constitute a...
-
Professor Walid Khaled
My laboratory works on defining the early cellular and molecular events that drive tumour initiation and development. In particular, we focus on how the cell of origin affects the differentiation trajectory of nascent tumour cells and dictates changes...
-
Mr Adam Palmer
-
Dr Avgi Andreou
-
Miss Alicia Garcia Gimenez
-
Mr Adrian Lascu
-
Miss Aleksandra Kruglikov
-
Dr Andrew Reynolds
-
Mr Angelos Kolias
Angelos Kolias is a Clinical Senior Lecturer and Consultant Neurosurgeon in the Department of Clinical Neurosciences, Addenbrooke’s Hospital and University of Cambridge, Cambridge, UK. He also holds an adjunct Professorship at Humanitas University,...
-
Dr Antony Rix
Co-founded by Prof Evis Sala and Dr Antony Rix, Lucida Medical is a spin-out from the University of Cambridge Department of Radiology and Cambridge University Hospitals. The company develops AI-based software to help automate the analysis of...
-
Professor Tony Green
Tony Green is Professor of Haemato-oncology in the University of Cambridge and honorary Consultant Haematologist at Addenbrookes Hospital. He was appointed Head of the University Department of Haematology (2000-2020), and in 2016 was appointed Director...
-
Mr Arqum Anwar
Rotation Project: The project aims to investigate the cellular role(s) of a novel factor expected to be involved in DNA damage response. Specifically, the interactome of the protein will be explored using co-immunoprecipitation followed by mass...
-
Dr Andreas Bender
Previously affiliated with the Lead Discovery Informatics (LDI) group of Novartis in Cambridge/MA, I am now developing and applying cheminformatics techniques in the drug discovery field in my group with the University of Cambridge. Our expertise ranges...
-
Professor Alan Warren
Our long-term goal is to elucidate the molecular mechanisms of ribosome assembly in eukaryotic cells and to understand how defects in this process cause bone marrow failure and cancer predisposition. Assembly of the two subunits of the ribosome,...
-
Dr Alasdair Russell
Alasdair heads up a specialised team that provide a centralised ‘Hub’ for the innovation and application of state-of-the-art Genome Editing technologies to complex, patient-relevant model systems in a pre-clinical setting. Further, we use these novel...
-
Dr Alexey Larionov
Hormonal treatment and resistance in Breast cancer Heritable cancer predisposition NGS data analysis
-
Dr Andrew Bannister
I have spent the last three decades generally messing around with chromatin with a special focus on histones and their modifications. My research has focused on identifying novel histone modifications together with characterization of the enzymes ...
-
Professor Anthony Davenport
Our research group focuses on understanding the role of G-protein-coupled receptors (GPCRs, targets for about ~50% of current drugs) together with their transmitters in humans. We use in vitro pharmacology and in vivo imaging using positron emission...
-
Dr Alex Cagan
My research seeks to understand the somatic evolutionary processes that occur within our bodies as we age and their consequences for health. Evolution is often considered to be an almost imperceptibly slow process. However, the cells that...
-
Dr Andre Neves
As a chemical engineer, I enjoy translating basic science into novel biomedical technologies. I am interested in the use of molecular imaging techniques for early cancer diagnosis and for better assessing response to cancer therapy. Currently, I'm...
-
Dr John Lizhe Zhuang
... that initiate BO and OAC. Firstly, I have established a series of patient derided organoid models from normal tissues, BO, and OAC, and ...
-
Professor Ming-Qing Du
... and molecular investigations. We have been undertaking a series of research programmes to elucidate the pathology, immunophenotype, and ...
-
Dr Alan Wright
(tbc) ...
-
Dr Anne-Laure Vallier
(tbc) ...
-
Dr Anne Roberts
(tbc) ...
-
Dr Ben Uttenthal
(tbc) ...
-
Mrs Beverley Haynes
(tbc) ...
-
Dr Chi Wong
(tbc) ...
-
Dr Dora Foukaneli
(tbc) ...
-
Dr Dude DuQuesne
TBC (test account for DC Systems - do not delete, just set status to ...
-
Professor Greg Hannon
(tbc) ...
-
Dr Jem Rashbass
(tbc) ...